DNA损伤反应改变预测肌浸润性膀胱癌新辅助化疗的敏感性:SWOG S1314 试验的相关分析。

IF 5.3 2区 医学 Q1 ONCOLOGY
JCO precision oncology Pub Date : 2024-11-01 Epub Date: 2024-11-05 DOI:10.1200/PO.24.00287
Gopa Iyer, Catherine M Tangen, Michal Sarfaty, Ashley M Regazzi, I-Ling Lee, Megan Fong, Woonyoung Choi, Colin P N Dinney, Thomas W Flaig, Ian M Thompson, Seth P Lerner, David J McConkey, Jonathan E Rosenberg
{"title":"DNA损伤反应改变预测肌浸润性膀胱癌新辅助化疗的敏感性:SWOG S1314 试验的相关分析。","authors":"Gopa Iyer, Catherine M Tangen, Michal Sarfaty, Ashley M Regazzi, I-Ling Lee, Megan Fong, Woonyoung Choi, Colin P N Dinney, Thomas W Flaig, Ian M Thompson, Seth P Lerner, David J McConkey, Jonathan E Rosenberg","doi":"10.1200/PO.24.00287","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Alterations in DNA damage response (DDR) genes, including <i>ERCC2</i>, have been correlated with response to neoadjuvant cisplatin-based chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). The SWOG 1314 (S1314) trial enrolled patients with MIBC who received one of two NAC regimens followed by radical cystectomy. We examined the prevalence of DDR alterations in NAC responders versus nonresponders and correlated DDR alteration status with response.</p><p><strong>Methods: </strong>Pretreatment tumor specimens from 179 evaluable patients underwent next-generation sequencing (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets assay). Associations were determined between any or only deleterious alterations within nine predefined DDR genes, or any alterations in <i>ERCC2</i>, and progression-free survival (PFS) and overall survival using Cox regression, and, in a subset of evaluable patients, pathologic response (complete response, pT0, or downstaging to <pT2) using logistic regression, adjusting for clinical stage and performance status.</p><p><strong>Results: </strong>Deleterious DDR alterations were detected in 41 (23%) of 179 patients. Of the 151 patients evaluable for pathologic response, patients with deleterious DDR alterations (n = 39) demonstrated a higher pathologic response rate than those without (odds ratio [OR], 3.24 [95% CI, 1.51 to 6.94]; <i>P</i> = .003). In 24 <i>ERCC2</i>-mutant patients, the OR for pT0 was 3.33 (95% CI, 1.35 to 8.22; <i>P</i> = .009) and for <pT2 was 2.33 (95% CI, 0.92 to 5.89; <i>P</i> = .073). The association between deleterious DDR alterations and PFS provided an estimate of hazard ratio, 0.54 (95% CI, 0.29 to 1.01; <i>P</i> = .053).</p><p><strong>Conclusion: </strong>Deleterious DDR alterations were associated with pathologic response following NAC in S1314. Functional validation of <i>ERCC2</i> and other DDR alterations is underway to help refine such alterations as biomarkers of NAC in patients with bladder cancer.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.\",\"authors\":\"Gopa Iyer, Catherine M Tangen, Michal Sarfaty, Ashley M Regazzi, I-Ling Lee, Megan Fong, Woonyoung Choi, Colin P N Dinney, Thomas W Flaig, Ian M Thompson, Seth P Lerner, David J McConkey, Jonathan E Rosenberg\",\"doi\":\"10.1200/PO.24.00287\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Alterations in DNA damage response (DDR) genes, including <i>ERCC2</i>, have been correlated with response to neoadjuvant cisplatin-based chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). The SWOG 1314 (S1314) trial enrolled patients with MIBC who received one of two NAC regimens followed by radical cystectomy. We examined the prevalence of DDR alterations in NAC responders versus nonresponders and correlated DDR alteration status with response.</p><p><strong>Methods: </strong>Pretreatment tumor specimens from 179 evaluable patients underwent next-generation sequencing (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets assay). Associations were determined between any or only deleterious alterations within nine predefined DDR genes, or any alterations in <i>ERCC2</i>, and progression-free survival (PFS) and overall survival using Cox regression, and, in a subset of evaluable patients, pathologic response (complete response, pT0, or downstaging to <pT2) using logistic regression, adjusting for clinical stage and performance status.</p><p><strong>Results: </strong>Deleterious DDR alterations were detected in 41 (23%) of 179 patients. Of the 151 patients evaluable for pathologic response, patients with deleterious DDR alterations (n = 39) demonstrated a higher pathologic response rate than those without (odds ratio [OR], 3.24 [95% CI, 1.51 to 6.94]; <i>P</i> = .003). In 24 <i>ERCC2</i>-mutant patients, the OR for pT0 was 3.33 (95% CI, 1.35 to 8.22; <i>P</i> = .009) and for <pT2 was 2.33 (95% CI, 0.92 to 5.89; <i>P</i> = .073). The association between deleterious DDR alterations and PFS provided an estimate of hazard ratio, 0.54 (95% CI, 0.29 to 1.01; <i>P</i> = .053).</p><p><strong>Conclusion: </strong>Deleterious DDR alterations were associated with pathologic response following NAC in S1314. Functional validation of <i>ERCC2</i> and other DDR alterations is underway to help refine such alterations as biomarkers of NAC in patients with bladder cancer.</p>\",\"PeriodicalId\":14797,\"journal\":{\"name\":\"JCO precision oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO precision oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1200/PO.24.00287\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO precision oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/PO.24.00287","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:包括ERCC2在内的DNA损伤应答(DDR)基因的改变与肌浸润性膀胱癌(MIBC)患者对顺铂新辅助化疗(NAC)的反应有关。SWOG 1314(S1314)试验招募了肌肉浸润性膀胱癌患者,他们接受了两种 NAC 方案中的一种,随后进行了根治性膀胱切除术。我们研究了NAC应答者与非应答者中DDR改变的发生率,并将DDR改变状态与应答相关联:179例可评估患者的治疗前肿瘤标本接受了新一代测序(纪念斯隆-凯特琳癌症靶点可操作突变综合分析)。采用Cox回归法测定了9个预定义DDR基因中的任何或仅有的有害改变或ERCC2中的任何改变与无进展生存期(PFS)和总生存期之间的关系,并在可评估患者的子集中测定了病理反应(完全反应、pT0或降期至结果):在179例患者中,有41例(23%)检测到有害的DDR改变。在可评估病理反应的 151 例患者中,有致畸性 DDR 改变的患者(n = 39)的病理反应率高于无致畸性 DDR 改变的患者(几率比 [OR],3.24 [95% CI,1.51 至 6.94];P = .003)。在24例ERCC2突变患者中,pT0的OR为3.33(95% CI,1.35至8.22;P = .009),P = .073)。有害DDR改变与PFS之间的关联提供了一个估计的危险比,即0.54(95% CI,0.29至1.01;P = .053):结论:畸变的DDR改变与S1314患者NAC治疗后的病理反应有关。目前正在对ERCC2和其他DDR改变进行功能验证,以帮助完善这些改变作为膀胱癌患者NAC生物标志物的功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.

Purpose: Alterations in DNA damage response (DDR) genes, including ERCC2, have been correlated with response to neoadjuvant cisplatin-based chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). The SWOG 1314 (S1314) trial enrolled patients with MIBC who received one of two NAC regimens followed by radical cystectomy. We examined the prevalence of DDR alterations in NAC responders versus nonresponders and correlated DDR alteration status with response.

Methods: Pretreatment tumor specimens from 179 evaluable patients underwent next-generation sequencing (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets assay). Associations were determined between any or only deleterious alterations within nine predefined DDR genes, or any alterations in ERCC2, and progression-free survival (PFS) and overall survival using Cox regression, and, in a subset of evaluable patients, pathologic response (complete response, pT0, or downstaging to

Results: Deleterious DDR alterations were detected in 41 (23%) of 179 patients. Of the 151 patients evaluable for pathologic response, patients with deleterious DDR alterations (n = 39) demonstrated a higher pathologic response rate than those without (odds ratio [OR], 3.24 [95% CI, 1.51 to 6.94]; P = .003). In 24 ERCC2-mutant patients, the OR for pT0 was 3.33 (95% CI, 1.35 to 8.22; P = .009) and for P = .073). The association between deleterious DDR alterations and PFS provided an estimate of hazard ratio, 0.54 (95% CI, 0.29 to 1.01; P = .053).

Conclusion: Deleterious DDR alterations were associated with pathologic response following NAC in S1314. Functional validation of ERCC2 and other DDR alterations is underway to help refine such alterations as biomarkers of NAC in patients with bladder cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.10
自引率
4.30%
发文量
363
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信